At Penn Medicine, patients with gastrointestinal stromal tumors (GISTs) receive their care from a multidisciplinary team of nationally recognized experts in the diagnosis, treatment and research of gastrointestinal cancer.
Gastrointestinal stromal tumors (GISTs) are a type of soft tissue tumor. GISTs are very rare tumors that start in special cells in the wall of the GI tract, called the interstitial cells of cajal. These cells, often called the “pacemaker cells,” regulate body processes like digestion and send signals to the muscles within the gastrointestinal tract to expand and contract, moving food and liquid through the digestive system.
GISTs can occur anywhere within the digestive tract, but are found most frequently in the stomach or small intestine.
Penn Medicine’s multidisciplinary approach to cancer diagnosis and treatment provides better outcomes and gives patients with GIST access to the most advanced treatment, surgical techniques and clinical trials.
Because navigating a cancer diagnosis and treatment options can be difficult, patients who wish to connect with a cancer specialist at Penn Medicine can speak with a cancer nurse, who can help them make an appointment with the right physician.
To connect with a cancer nurse at Penn Medicine, patients should call 800-789-PENN.
Some risk factors for cancer, like age and family history, cannot be prevented. Patients who feel they are at risk may benefit from consulting with a risk assessment specialist within Penn Medicine’s GI genetics program.
Risk factors affect the chance of developing GISTs. Having a risk factor, or even several, does not mean that someone will get cancer.
Most GISTs are sporadic, meaning they have no association with any specific risk factor. But like many cancers, GISTs occur most in people over the age of 50, and they occur both in men and women. In rare cases, GISTs have been found in members of the same family suggesting a familial risk.
Because there are no known environmental or behavioral risk factors, there are no recommended preventative guidelines for GIST. People with genetic syndromes that have been found to increase their risk should speak with their physicians about screening for or preventing GISTs.
Penn Medicine offers programs for patients who want to determine their risk of developing gastrointestinal cancer through GI genetics program.
These programs offer knowledge about the presence of genetic risk factors for cancer and provide patients with important, sometimes life-saving options.
Many patients with small GISTs report no symptoms. Large GISTs may cause symptoms similar to those of other tumors in the digestive tract. The most common symptom is gastrointestinal bleeding.
Symptoms of GISTs may include:
Sometimes, GISTs can rupture, or cause a gastrointestinal obstruction. In those cases, immediate medical attention is required.
Staging systems provide doctors with a common language for describing tumors. After cancer is first diagnosed, a series of tests are used to determine the extent of the cancer and to see whether it has spread to other parts of the body from where it started. Staging is a way of recording the size and growth of a cancer, and developing the plan for treatment. By understanding the stage of their cancer, patients can make informed decisions about their treatment.
Because there is no standard system, many doctors classify gastrointestinal carcinoid tumors into one of three general stages:
After being diagnosed with GIST, patients at the Abramson Cancer Center may be evaluated through the Gastrointestinal Cancer Evaluation Center (GICEC). The center provides patients with expert support and evaluation to discuss treatment options and individualized treatment plans.
Patients with GISTs are treated by a multidisciplinary team of cancer specialists who see more patients with gastrointestinal (GI) cancers in one year than many doctors see in their careers.
Penn Medicine’s GI cancer program has physicians nationally recognized for their expertise in the diagnosis and treatment of cancer.
Penn’s GI cancer treatment team includes:
Penn’s GI cancer program is also supported by a robust research program with immediate translation from bench to bedside.
Many treatment options including standard treatments and clinical trials are available for patients with GIST.
Patients at Penn Medicine can benefit from participating in clinical trials that take place at Penn. Patients interested in learning more about clinical trials should speak with someone on their treatment team.
Every step of cancer treatment – from cancer diagnosis, to surgery and treatment to forming a survivorship plan – comes with different needs and issues that should be addressed.
Oncology Navigation Specialists at the Abramson Cancer Center are available to make a patient’s experience as seamless as possible. As experts in navigating complex health care situations, patient navigation specialists serve as a consistent point of contact and a reliable source for advice, support and direction for patients and families. They can help in a variety of ways including; provide emotional support, identify resources, and ensure access to information, support services, educational programs and community resources.
Learn more about Oncology Navigation Specialists at the Abramson Cancer Center.
An accurate cancer diagnosis from trusted cancer specialists is the first step in getting personalized treatment options to treat gastrointestinal stromal tumors (GISTs).
Patients who choose Penn Medicine’s Abramson Cancer Center, benefit from a multidisciplinary team of cancer specialists including gastroenterologists, radiologists, pathologists and surgeons who work together to provide a diagnosis and treatment plan custom designed for each patient with GISTs.
Cancer specialists at Penn Medicine are highly experienced in using the most advanced techniques for diagnosing gastrointestinal stromal tumors and are actively researching better and more precise ways to detect GISTs.
Navigating a cancer diagnosis and treatment options can be difficult, patients who wish to connect with a cancer specialist at Penn Medicine can speak with a cancer nurse, who can help them make an appointment with the right person. Penn Medicine’s contact center has experienced cancer nurses available and ready to guide patients in finding the cancer specialist right for them.
To connect with a cancer nurse at Penn Medicine, patients should call 800-789-PENN (7366).
Currently, there are no recommendations for screening the general public for GIST, such as mammograms or colonoscopies. However, people who are at increased risk for GIST should talk to their physicians about anal cancer screening.
GISTs may be found early by chance, such as during another examination like an endoscopy. Rarely, a GIST may be seen on an imaging test like a CT scan is performed for other reasons.
Penn Medicine’s multidisciplinary treatment team includes nationally recognized pathologists and radiologists who are experts at finding and diagnosing cancer.
If physicians suspect cancer, they might perform or order one or more of these tests to diagnosis and stage GISTs:
Staging is a way of describing cancer, such as where it is located, if or where it has spread, and if it is affecting the functions of other organs in the body. Doctors use diagnostic tests to determine the cancer's stage, so staging may not be complete until all the tests are finished. Knowing the stage helps the doctor to decide what kind of treatment is best and can help predict a patient's chance of recovery.
Physicians at Penn Medicine use the TNM staging system:
The T stage represents the extent of the primary tumor itself.
The N stage represents the degree of the involvement of the lymph nodes.
The M stage represents whether or not there is spread of cancer to other parts of the body.
The “staging diagnosis” combines the T, N and M groups into four stages (Stage I-IV); some of which have subtypes (a or b) according to overall tumor characteristics.
Physicians at Penn often classify tumors by whether or not they can be resected, or surgically removed. There are three ways physicians look at tumors:
In the case of gastrointestinal stromal tumors, the mitotic rate is also measured. The mitotic rate, described as either low or high, is a measure of how fast the cancer cells are growing and dividing. A low mitotic rate predicts a better outcome.
Following the diagnosis and staging of GISTs, cancer specialists at Penn’s Abramson Cancer Center develop a personalized treatment plan. Penn’s treatment options for GISTs include:
Because navigating a cancer diagnosis and treatment options can be difficult, patients who wish to connect with a cancer specialist at Penn Medicine can speak with a cancer nurse, who can help them make an appointment with the right physician.
To connect with a cancer nurse at Penn Medicine, patients should call 800-789-PENN (7366).
Many tumors are successfully treated with surgery only. Complete removal of the entire tumor is the standard treatment when possible. When complete removal of the tumor is not possible, surgeons often remove as much of the tumor as possible to provide some relief from symptoms.
Penn Medicine offers patients one of the largest gastrointestinal surgical programs in the United States with a nationally recognized record for high-quality patient care and long-term survival.
During this operation, the surgeon removes the primary tumor and a margin of tissue around the primary location. Lymph nodes may also be removed, although lymph node metastasis is rare with GIST, and lymphadenectomy of clinically uninvolved nodes is not necessary. Most localized tumors can be surgically removed through a skin incision, but a rectal carcinoid tumor may be removed using an endoscope.
This surgery removes a portion of the upper part of the rectum.
If the tumor has spread to the liver, this surgery removes the cancer from the liver. It often helps relieve or reduce the symptoms of carcinoid syndrome.
Typically, gastrointestinal stromal tumors (GISTs) are treated with surgery and medical oncological treatments, including chemotherapy and biological therapies.
Depending on the type of tumor, location and size, radiation may be used. However, its use to treat GISTs is rare.
Penn Medicine specializes in a team approach to treatment with interdisciplinary care and innovative approaches that use chemotherapy and biologic therapies.
Penn’s medical oncologists are combining personalized care with personalized medicine to create targeted immunotherapies for the treatment of cancer. Targeted immunotherapies such as tyrosine kinase inhibitor (TKI) therapy stimulate the immune system to work harder, allowing it to recognize the difference between healthy cells and cancer cells and working to eliminate those that become cancerous. TKI therapy has significantly increased survival rates.
Today, more and more people are surviving cancer. Clinical trials benefit patients with access to breakthrough therapies and treatments. These new advances in cancer treatment are occurring every day at Penn Medicine, giving patients hope that even greater discoveries lie ahead. Through clinical trials:
In addition to standard treatments and clinical trials, patients at Penn Medicine may wish to add additional therapies and treatments such as massage therapy, acupuncture and art therapy. These therapies do not have curative intent, and are designed to complement standard treatments, not take their place.
At Penn Medicine, integrative medicine and wellness services can supplement traditional cancer treatments such as chemotherapy, surgery and radiation therapy. While conventional medicine plays a critical role in eradicating cancer, integrative medicine and wellness programs offer patients and their families ways to enhance the quality of their lives, minimize or reduce the side effects of cancer and cancer treatment, and promote healing and recovery.
The physicians at Penn Medicine are knowledgeable and supportive of complementary cancer treatments. The cancer team works with patients and families to integrate these supportive programs into the overall care plan, while ensuring the safety and health of patients.
The Abramson Cancer Center’s range of integrative supportive services is designed to help patients cope with the cancer experience and improve their overall sense of well-being. Services include:
The Joan Karnell Cancer Center at Pennsylvania Hospital offers a variety of supportive care programs for patients and families, from diagnosis through survivorship. These programs are available at no cost to the patients treated at Pennsylvania Hospital, and some are open to patients treated elsewhere. These services include social work counseling, nutrition counseling, psychological counseling and spiritual counseling.
The Cancer Appetite and Rehabilitation Clinic focuses on patients with loss of appetite and weight.
The Supportive Care Clinic helps patients manage cancer-related symptoms and goals of care.
Integrative support programs include:
Support groups and educational programs are available at Pennsylvania Hospital throughout the year.
Palliative care provides medical and non-medical interventions to ease the symptoms of cancer and its treatment. Palliative care includes physical, emotional and spiritual care that can enhance the quality of life for cancer patients.
Palliative care can be used to complement traditional cancer therapies, or to improve quality of life when curative therapies are no longer an option.
Palliative care is an approach to patient care that can be integrated with curative therapies at any point from diagnosis to survivorship or end-of-life care.
Palliative care services include palliative chemotherapy, radiation therapy and surgery as well as psychological counseling, art therapy and support groups for patients and families. The goals of palliative care are to enhance the quality of life for cancer patients and their families, and provide emotional and spiritual support to enhance personal growth.
Palliative care services are offered at the Hospital of the University of Pennsylvania and Pennsylvania Hospital.
Penn Home Care and Hospice Services offer a full range of home health care needs by partnering three top-level home health care services under one roof:
Penn Home Care and Hospice Services offer an array of specialized therapies and medications for patients with cancer and cancer-related conditions.
There are more than 12 million cancer survivors living and thriving today as a result of advances in cancer treatment. However, cancer treatments can result in physical, emotional and financial complications long after the therapy is complete. Survivorship programs at Penn Medicine are a distinct phase of gastrointestinal stromal tumor (GIST) care and are designed to help patients' transition from their cancer treatment routine to a post-cancer care lifestyle.
At the end of treatment, GIST patients should schedule a survivorship visit with their oncologist and nurse practitioner. At this time, patients are provided with a summary of the treatment received as well as a plan for follow-up care.
Long-term cancer survivors should speak to their oncologist and nurse practitioner about scheduling a one-time, survivorship-focused consultation with a nurse practitioner or physician. Annual or more frequent follow-up appointments are also available.
Penn cancer providers work one-on-one with patients to develop survivorship care plans. Since every cancer is unique, the plans are tailored to the patients.
The survivorship care plan includes information on:
A survivorship care plan encourages patients to review the information with their health care team and become active participants in their follow-up care.
Penn also offers GIST patients a number of support programs and groups to enhance their survivorship care plans.
Every step of cancer treatment – from cancer diagnosis, to surgery and treatment to forming a survivorship plan – comes with different needs and issues that should be addressed.
Oncology Navigation Specialists at the Abramson Cancer Center are available to make a patient’s experience as seamless as possible. As experts in navigating complex health care situations, patient navigation specialists serve as a consistent point of contact and a reliable source for advice, support and direction for patients and families. They can help in a variety of ways including; provide emotional support, identify resources, and ensure access to information, support services, educational programs and community resources.
Learn more about Oncology Navigation Specialists at the Abramson Cancer Center.
Penn Medicine’s Living Well After Cancer™ Program is a nationally recognized program that focuses on issues facing cancer survivors. In 2007, the Abramson Cancer Center was designated a LIVESTRONG™ Survivorship Center of Excellence Network. The Abramson Cancer Center is only one of eight LIVESTRONG centers in the United States, and is the only LIVESTRONG Survivorship Center of Excellence in the Philadelphia region. The program focuses on survivorship, a distinct phase of care.
Prescription for Living: The Cancer Survivorship Program at the Joan Karnell Cancer Center at Pennsylvania Hospital, provides patients with a summary of important information about specific cancer diagnoses and treatments, as well as follow-up information and steps to take towards recovery, supportive care and education to help patients adjust to their lives as cancer survivors.
Penn offers cancer patients support programs and groups to enhance their survivorship care plans.
The Abramson Cancer Center and Joan Karnell Cancer Center at Pennsylvania Hospital offer a wide range of materials and host many activities that provide education and support to address key areas of concern including survivorship for cancer patients and their loved ones.
Focus On: Gastrointestinal Cancers is a day-long conference that addresses issues for patients with gastrointestinal cancer, as well as their loved ones.
Nicholas Martell was first diagnosed with prostate cancer more than ten years ago. He was healthy for many years after being treated with radiation therapy. Nick recently experienced a recurrence of his cancer. Physicians at Penn tailored his treatment and enrolled him in a new Phase I clinical trial using laser-based photodynamic therapy (PDT) followed by hormone therapy. This leading edge treatment plan was effective. Nick just returned from a vacation with his daughter, and in his free time, he plays golf every chance he gets.
Peter O'Dwyer, MD, professor of Hematology-Oncology and program director of Development Therapeutics in the Abramson Cancer Center, was interviewed on NBC10's 10! Show about Penn's work as part of the Stand Up to Cancer Dream Team... Read more